Nektar Therapeutics Surpasses Q4 Revenue and EPS Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy NKTR?
Source: seekingalpha
- Performance Beat: Nektar Therapeutics saw a 6% increase in early trading on Friday, reporting a GAAP EPS of -$1.78 for Q4, surpassing estimates by $0.69, while revenue of $21.81 million exceeded expectations by $11.4 million, indicating a positive shift in financial performance.
- Annual Revenue Decline: Despite the strong Q4 results, total revenue for 2025 was $55.2 million, significantly down from $98.4 million in 2024, primarily due to the cessation of product sales following the sale of the Huntsville manufacturing facility, highlighting the impact of strategic divestitures on revenue.
- Significant R&D Progress: CEO Howard W. Robin noted that 2025 was pivotal, with promising Phase 2 data for rezpegaldesleukin in atopic dermatitis and alopecia areata, with plans to initiate a Phase 3 trial in June 2026, further advancing product development.
- Optimistic Financial Outlook: CFO Sandra Gardiner provided preliminary guidance for 2026, expecting non-cash royalty revenue between $40 million and $45 million, R&D expenses of $200 million to $250 million, and an end-of-year cash and investments target of $400 million to $460 million, reflecting improved financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 75.710
Low
102.00
Averages
123.43
High
165.00
Current: 75.710
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Encourages Nektar Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, particularly for investors who purchased or acquired securities between February 26, 2025, and December 15, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a strong commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Nektar is May 5, 2026, emphasizing the importance of timely action to protect investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruq & Faruqi's investigation indicates the proactive role legal institutions play in safeguarding investor interests, which could impact Nektar's market reputation and stock performance.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns regarding the company's compliance and operations.
- Allegations of False Statements: The complaint alleges that Nektar's executives made materially false and misleading statements during the class period, particularly regarding the enrollment and results of the REZOLVE-AA trial, which may have led investors to misjudge the company's prospects.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal system's role in protecting investor rights.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only upon successful recovery, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Nektar Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to discuss their rights and ensure proper representation in the class action, avoiding the risk of being an absent class member.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered losses, highlighting significant failures in the company's disclosure practices that could have long-term negative effects on its stock price and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results.
- Investor Rights Protection: Investors have until May 5, 2026, to apply as Lead Plaintiff in the class action, with Pomerantz LLP emphasizing its expertise in securities fraud and corporate misconduct to advocate for victim compensation.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, indicating significant deficiencies in the company's information disclosure practices, which may lead to future legal and financial repercussions.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
Faruqi & Faruqi Encourages Nektar Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, particularly for investors who purchased or acquired securities between February 26, 2025, and December 15, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a strong commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Nektar is May 5, 2026, emphasizing the importance of timely action to protect investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruq & Faruqi's investigation indicates the proactive role legal institutions play in safeguarding investor interests, which could impact Nektar's market reputation and stock performance.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns regarding the company's compliance and operations.
- Allegations of False Statements: The complaint alleges that Nektar's executives made materially false and misleading statements during the class period, particularly regarding the enrollment and results of the REZOLVE-AA trial, which may have led investors to misjudge the company's prospects.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal system's role in protecting investor rights.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only upon successful recovery, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Nektar Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to discuss their rights and ensure proper representation in the class action, avoiding the risk of being an absent class member.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered losses, highlighting significant failures in the company's disclosure practices that could have long-term negative effects on its stock price and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results.
- Investor Rights Protection: Investors have until May 5, 2026, to apply as Lead Plaintiff in the class action, with Pomerantz LLP emphasizing its expertise in securities fraud and corporate misconduct to advocate for victim compensation.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, indicating significant deficiencies in the company's information disclosure practices, which may lead to future legal and financial repercussions.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
